CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group

Gan to kagaku ryoho. Cancer & chemotherapy

Volumn 29, Issue 5, 2002, Pages 741-749

  Kimijima, Izo ^a   Tominaga, Takeshi ^a   Nomizu, Tadashi ^a   Nomura, Yasuo ^a   Takashima, Shigemitsu ^a   Koyama, Hiroki ^a   Sano, Muneaki ^a   Tohge, Tetsuya ^a   Ueo, Hiroaki ^a   Ikeda, Seiyo ^a   Ohashi, Yasuo ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ENZYME INHIBITOR; ESTROGEN; LETROZOLE; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; SURVIVAL RATE; TRIAZOLES;

EID: 0036560729     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)